Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03359395 · ClinicalTrials.gov registry record · Phase 4
Pre-medication With Alfentanil vs Placebo During ECT
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT03359395 is a Phase 4 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 100 participants.
The verdict
NCT03359395, a Phase 4 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
Hemodynamic changes associated with the conduct of electroconvulsive therapy may be minimized with the administration of alfentanil as part of their anesthetic regimen. This study proposes to compare the effects in a blinded fashion. Currently alfentanil is an FDA approved drug used on a daily basis by anesthesiologists on other surgeries so this is not a new indication.
Interventions
- DRUG Placebos
- DRUG Alfentanil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-06-04 |
| Est. Completion | 2020-02-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03359395
The ClinicalTrials.gov registry entry for NCT03359395 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03359395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03359395 about?
NCT03359395 is a clinical study titled "Pre-medication With Alfentanil vs Placebo During ECT". Hemodynamic changes associated with the conduct of electroconvulsive therapy may be minimized with the administration of alfentanil as part of their anesthetic regimen. This study proposes to compare the effects in a blinded fashion. Currently alfentanil is an FDA approved drug used on a daily basis...
What is the current status of trial NCT03359395?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2018-06-04. Estimated completion is 2020-02-17.
What interventions are being tested in trial NCT03359395?
The interventions under investigation include: Placebos (DRUG), Alfentanil (DRUG).
Who is sponsoring clinical trial NCT03359395?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.